Log in
Enquire now
Mind Medicine, Inc.

Mind Medicine, Inc.

Toronto-based company developing drugs for use in psychedelic therapy protocols.

OverviewStructured DataIssuesContributors

Contents

mindmed.co
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Technology
Technology
Pharmaceutical industry
Pharmaceutical industry
‌
Psychedelic therapy
Biomedical engineering
Biomedical engineering
Biology
Biology
Biotechnology
Biotechnology
Engineering
Engineering
Location
New York City
New York City
Vancouver
Vancouver
Toronto
Toronto
CEO
Stephen L. Hurst
Stephen L. Hurst
Founder
Jamon Rahn
Jamon Rahn
Stephen L. Hurst
Stephen L. Hurst
‌
Scott Freeman, MD
‌
Leonard Latchman
Pitchbook URL
pitchbook.com/profiles...277525-00
Legal Name
Mind Medicine Inc.
Date Incorporated
2010
Number of Employees (Ranges)
51 – 2000
Number of Employees
730
Full Address
One World Trade Center Suite 8500 New York, NY 10007 United States
Investors
Canadian Imperial Bank of Commerce
Canadian Imperial Bank of Commerce
‌
Dan Capelle
‌
Canaccord Genuity Group Inc.
Eight Capital
Eight Capital
Founded Date
2019
Total Funding Amount (USD)
200,303,000
Latest Funding Round Date
September 2022
Exchange
Nasdaq
Nasdaq
Former CEO
Jamon Rahn
Jamon Rahn
Latest Funding Type
Initial public offering (IPO)
Initial public offering (IPO)
Patents Assigned (Count)
1
Country
United States
United States

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
30,000,000
Ticker Symbol
MNMD

Mind Medicine (MindMed) Inc. announced that in collaboration with University Hospital Basel's Liechti Laboratory, it has discovered and filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.

This discovery, when further developed, may act as the 'off-switch' to an LSD trip.

MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.

The invention may help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects when required by a patient or medical professional.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

MindMed CEO Rob Barrow at Web Summit 2021: Therapy 2.0 - The next step in mental health

https://www.youtube.com/watch?v=O5GBvUP90Kc

Web

February 1, 2022

References

Find more companies like Mind Medicine, Inc.

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.